Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients

Highlights • Assess the prophylactic efficacy of tetracycline on afatinib induced-skin-toxicity. • Pre-emptive tetracycline reduce rash incidence and severity associated with afatinib. • Any adverse event associated with pre-emptive tetracycline treatment.

Saved in:
Bibliographic Details
Published inLung cancer (Amsterdam, Netherlands) Vol. 88; no. 3; pp. 282 - 288
Main Authors Arrieta, Oscar, Vega-González, María Teresa, López-Macías, Diego, Martínez-Hernández, Jorge Negueb, Bacon-Fonseca, Ludwing, Macedo-Pérez, Eleazar Omar, Ramírez-Tirado, Laura Alejandra, Flores-Estrada, Diana, de la Garza-Salazar, Jaime
Format Journal Article
LanguageEnglish
Published Ireland 01.06.2015
Subjects
Adult
Aged
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Carcinoma, Non-Small-Cell Lung - complications
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - pathology
Female
Hematology, Oncology and Palliative Medicine
Humans
Lung Neoplasms - complications
Lung Neoplasms - drug therapy
Lung Neoplasms - pathology
Male
Middle Aged
Neoplasm Staging
Pre-Exposure Prophylaxis
Pulmonary/Respiratory
Quinazolines - adverse effects
Quinazolines - therapeutic use
Risk Factors
Skin Diseases - chemically induced
Skin Diseases - diagnosis
Skin Diseases - prevention & control
Tetracycline - therapeutic use
Tirosine kinase inhibitors
Afatinib
Skin toxicities
Toxicity severity
Non-small cell lung cancer
Tetracycline
Online AccessGet full text

Cover

More Information
Summary:Highlights • Assess the prophylactic efficacy of tetracycline on afatinib induced-skin-toxicity. • Pre-emptive tetracycline reduce rash incidence and severity associated with afatinib. • Any adverse event associated with pre-emptive tetracycline treatment.
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2015.03.019